Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Autor
Zavala, Valentina A.Casavilca-Zambrano, Sandro
Navarro-Vásquez, Jeannie
Castañeda, Carlos A.
Valencia, Guillermo
Morante, Zaida
Calderón, Monica
Abugattas, Julio E.
Gómez, Henry
Fuentes, Hugo A.
Liendo-Picoaga, Ruddy
Cotrina, Jose M.
Monge, Claudia
Neciosup, Silvia P.
Huntsman, Scott
Hu, Donglei
Sánchez, Sixto E.
Williams, Michelle A.
Núñez-Marrero, Angel
Godoy, Lenin
Hechmer, Aaron
Olshen, Adam B.
Dutil, Julie
Ziv, Elad
Zabaleta, Jovanny
Gelaye, Bizu
Vásquez, Jule
Gálvez-Nino, Marco
Enriquez-Vera, Daniel
Vidaurre, Tatiana
Fejerman, Laura
Fecha de publicación
2022-08-01Palabras clave
Breast NeoplasmsFemale
Hispanic or Latino
Humans
Logistic Models
Peru
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
United States
Metadatos
Mostrar el registro completo del ítemJournal
Cancer Epidemiology Biomarkers and PreventionDOI
10.1158/1055-9965.EPI-22-0069Enlaces adicionales
https://aacrjournals.org/cebp/article/31/8/1602/707138/Association-between-Ancestry-Specific-6q25Resumen
Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.Tipo
info:eu-repo/semantics/articleDerechos
info:eu-repo/semantics/openAccessAttribution-NonCommercial-ShareAlike 4.0 International
Idioma
engISSN
10559965EISSN
15387755Patrocinadores
National Institutes of Healthae974a485f413a2113503eed53cd6c53
10.1158/1055-9965.EPI-22-0069
Scopus Count
Colecciones
El ítem tiene asociados los siguientes ficheros de licencia:
- Creative Commons
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess